By James Baumgarden, PhD
PRECISIONheor
CAR-T therapy breaks a pattern of stagnant efficacy growth in pharmaceutical innovation. A new CAR-T therapy study, by Precision’s James Baumgarden and his study co-authors, demonstrates significantly greater incremental effectiveness and similar cost–effectiveness to previous anticancer treatments.